metallothionein and Hepatoblastoma

metallothionein has been researched along with Hepatoblastoma* in 3 studies

Other Studies

3 other study(ies) available for metallothionein and Hepatoblastoma

ArticleYear
MT1G hypermethylation: a potential prognostic marker for hepatoblastoma.
    Pediatric research, 2010, Volume: 67, Issue:4

    Hepatoblastoma comprises only 1% of all cancers in childhood. Because of its low frequency, a small number of prognostic factors are described in hepatoblastoma and most of them are related to resectability. Microarray studies showed a large number of underexpressed genes in hepatoblastoma. Because aberrant DNA methylation has been recognized as an alternative mechanism for tumor suppressor gene inactivation, this could be involved with gene downregulation in these tumors. Despite the rarity of hepatoblastoma, this study evaluated the methylation pattern of 25 genes in 20 paraffin-embedded tumor specimens and five non-neoplastic liver samples (normal control) by quantitative methylation-specific PCR (QMSP). The examination of the methylation profile of hepatoblastoma samples and normal liver specimens revealed a high tumor-specific DNA hypermethylation in the promoter regions of five genes (APC, CDH1, MT1G, RASSF1A, and SOCS1). Furthermore, MT1G hypermethylation showed a significant correlation with poor prognosis of patients with hepatoblastoma. This study represents the first quantitative evaluation of promoter hypermethylation in hepatoblastoma and demonstrated that aberrant methylation is a frequent event in this malignancy. Furthermore, our data provide evidence that MT1G hypermethylation may be useful as prognostic indicator for this disease and suggest that patients with hepatoblastoma may benefit from demethylating drug treatments.

    Topics: Adolescent; Biomarkers, Tumor; Child; Child, Preschool; DNA Methylation; Female; Hepatoblastoma; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metallothionein; Prognosis; Promoter Regions, Genetic; Retrospective Studies

2010
Chronic exposure of HepG2 cells to excess copper results in depletion of glutathione and induction of metallothionein.
    Toxicology in vitro : an international journal published in association with BIBRA, 2002, Volume: 16, Issue:2

    Metallothionein (MT) and reduced glutathione (GSH) play an important role in the intracellular handling of copper by preventing the generation and favouring the removal of copper-derived free radicals. The present study addressed the changes in MT and GSH that follow chronic (2 or 5 weeks) exposure of human hepatoblastoma cells (HepG2) to excess copper. Copper treatment (100 microM, 2 weeks) led to a 28-fold elevation in intracellular copper. Concomitantly, cells exhibited a seven-fold increase in total MT and an increment in its saturation with copper from 45 to 86%. Around 38% of copper in the cytosolic fraction could be accounted for by MT. GSH equivalents were substantially lowered (to 37% of basal levels) in treated cells, with only part of it being accounted for by an increase in GSSG. Copper-treatment induced no changes in catalase or GSH-peroxidase activities but it was associated with a small reduction in SOD (20%) and GSH-reductase (26%) activities. Copper-loaded cells did not differ from controls in their basal oxidative tone; however, when exposed to tert-butylhydroperoxide they exhibited a markedly greater susceptibility to undergo both oxidative stress and cell lysis. It is proposed that chronic exposure of HepG2 cells to excess copper is accompanied by "adaptive changes" in GSH and MT metabolism that would render cells substantially more susceptibility to undergo oxidative stress-related cytotoxicity.

    Topics: Adaptation, Physiological; Cell Death; Copper; Cytosol; Dose-Response Relationship, Drug; Enzyme Induction; Glutathione; Hepatoblastoma; Humans; Liver Neoplasms; Metallothionein; Oxidative Stress; tert-Butylhydroperoxide; Tumor Cells, Cultured

2002
Copper resistant human hepatoblastoma mutant cell lines without metallothionein induction overexpress ATP7B.
    Hepatology (Baltimore, Md.), 1998, Volume: 28, Issue:5

    Mutant human hepatoblastoma cell lines resistant to copper toxicity were isolated from mutagenized HuH7. Two copper resistant cell lines (CuR), CuR 23 and CuR 27, had reduced basal expression of metallothionein (MT) messenger RNA (mRNA) and exhibited minimal or no increase in resistance to cadmium or zinc toxicity. Copper uptake, efflux of newly transported copper, glutathione content, and efflux rate were comparable with HuH7, whereas holoceruloplasmin synthesis and secretion were slightly decreased. Subcellular distribution of copper at steady-state showed an increase in organelle and membrane fractions with a reduction in cytosol. Expression of ATP7B mRNA was fivefold increased, and ATP7B protein approximately threefold increased in both CuR 23 and 27. Another cell line, CuR 41, showed increased basal expression of MT and ATP7B mRNA but not ATP7B protein, and resistance to cadmium and zinc toxicity. Copper uptake in CuR 41 was comparable with HuH7, but initial rates of efflux of copper and glutathione were reduced. The synthesis of holoceruloplasmin but not ceruloplasmin peptide was markedly diminished in CuR 41. Subcellular distribution of copper showed an increase in cytosolic and decreased organelle and membrane-associated copper. These data suggest that cellular resistance to copper toxicity was achieved in two independent cell lines without MT induction and that the induction of ATP7B may lead to the enhanced intracellular sequestration of copper by organelles.

    Topics: Adenosine Triphosphatases; Blotting, Northern; Blotting, Western; Cadmium; Carrier Proteins; Cation Transport Proteins; Ceruloplasmin; Copper; Copper-Transporting ATPases; Drug Resistance; Gene Expression; Glutathione; Hepatoblastoma; Humans; Kinetics; Liver Neoplasms; Metallothionein; Mutagenesis; Protein Biosynthesis; RNA, Messenger; Tumor Cells, Cultured; Zinc

1998